Legislation passed by Congress and expected to be signed by President Barack Obama would allow the FDA to begin collecting user fees from generic drug makers on Oct. 1.
But passage of the FDA User Fee Corrections Act won't protect user fee programs from potential budget cuts under sequestration.

Related Summaries